“microbiome” Archives

in
Entry Author Date Location
Bio Roundup: Grail Acquisition, Libra’s Launch, Tau Trial Results & More 09/25/20 National
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More 09/18/20 National
Bio Roundup: Seres Soars, MesoBlast Vote, Duchenne Decision & More 08/14/20 National
Seres Sets Sights on FDA After C. Diff Microbiome Therapy Scores in Phase 3 08/10/20 Boston
In Microbiome Milestone, Finch Therapeutics C. diff Pill Bests Placebo 06/19/20 Boston
Bio Roundup: Acquisitive Alexion, CRISPR on COVID, C. diff Success & More 05/08/20 National
Why 2020 Is Pivotal for Microbiome Drug R&D (Or Maybe 2021, Given COVID-19) 04/22/20 National
Biotech Roundup: GSK’s Ante, Shakeup at Sage, Telehealth’s Rise & More 04/10/20 National
Gilead Heightens Inflammatory Disease Focus With Second Genome Microbiome Deal 04/08/20 San Francisco
Novome Lands $33M to Tweak a Gut Microbe Into a Metabolic Therapy 01/08/20 San Francisco
Investors Go With Gut Ahead of Microbiome Therapy Boom, Says Seventure 01/01/20 National
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone 09/06/19 National
Bankrupt uBiome Says Founders May Have Misled Investors 09/04/19 San Francisco
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More 08/23/19 National
Women’s Health-Focused Luca Bio Takes Microbiome R&D Beyond the Gut 08/06/19 Boston
Elanco Boosts Vaccine Portfolio With $60M Prevtec Acquisition 08/01/19 Indiana
PanTheryx Lands $50M to Use “First Milk” to Target Gut Microbiome 06/26/19 Boulder/Denver
Bio Roundup: Array Bio Acquired, IPO Spree, Sanofi’s Job Cuts & More 06/21/19 National
With Yale Tech and $12M, Artizan Aims for Root Cause of Gut Disease 06/10/19 Boston
Bio Roundup: Opioids in Court, IPO Parade, Brain Cancer Bet & More 05/31/19 National
With $35M, Whole Biome Eyes 2020 Launch of Medical Food for Diabetes 05/30/19 San Francisco
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More 05/03/19 National
Flagship Pioneering Unveils Kintai’s Gut Approach to Treating Disease 04/16/19 Boston
Bio Roundup: Golumbeski’s Legacy, CRISPR Moratorium, Rebate Week & More 03/15/19 National
Kaleido Bio Downsizes IPO, Raises $75M for Microbiome Drug Tests 02/27/19 Boston
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More 02/22/19 National
Seres Lays Off 30% of Staff, CSO Leaves After Pipeline Review 02/07/19 Boston
New CRISPR Fight: Old Friends Intellia, Caribou in License Dispute 02/06/19 San Francisco
UAS Laboratories Grabs $21.7M for Probiotics Manufacturing Business 01/31/19 Wisconsin
Kaleido Bio and Cirius Join an IPO Queue Stalled by Federal Shutdown 01/11/19 Boston
Page 1 of 5 next page »